• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics Inc (NQ: ARQT )

    8.310 -0.210 (-2.46%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Arcutis Biotherapeutics Inc

    < Previous 1 2 3 Next >
    Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Appoints David Topper as Chief Financial Officer
    Industry veteran with over 40 years of experience in finance, investment management, and investment banking 
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Promotes Todd Tucker to Chief Human Resources Officer
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Pricing of $150 Million Public Offering
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Proposed Public Offering
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.